US Patent Number
A novel organic cation transporter (OCT) gene, OCT 6, and use thereof is described. The OCT6 gene is preferentially expressed in human hematopoietic tissues, including CD34+ cells and leukemia cells. Its narrow tissue distribution, substrate specificity, and close homology to other cell membrane transporters make OCT6 an attractive target for the treatment of myeloid diseases.
University of Kentucky Research Foundation, Lexington, KY (US)
Moscow, Jeffrey A.; Lu, Xin; and Jordan, Craig, "Organic Cation Transporter Preferentially Expressed in Hematopoietic Cells and Leukemias and Uses Thereof" (2010). Markey Cancer Center Faculty Patents. 1.